New projects are expected to generate over $3 million of high margin revenue

Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive Review

FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested

Epique and Clear Mortgage: Shared Vision and Values

"Pioneering Fully Automated AI Customer Acquisition"

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES 

CXAI is shaping the future of work by enabling enhanced employee experiences using artificial intelligence

- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients

- Dermata continues discussions with potential botulinum toxin partners for DMT410

- Raised $2.3 million in net proceeds from financing completed in 2Q 2024